Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Can J Physiol Pharmacol ; 84(11): 1139-43, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17218978

ABSTRACT

Previous experiments have shown that chronic estrogen treatment via subcutaneous implants prevented insulin-induced blood pressure elevation and increased insulin sensitivity in ovariectomized female rats. In vitro vascular studies were performed using isolated mesenteric arteries to determine the effect of chronic estrogen and insulin treatments on vascular responses to vasoconstrictor agents. Female Wistar rats were assigned to the following groups: sham-operated, sham-operated plus insulin, sham-operated plus insulin plus estrogen, ovariectomized, ovariectomized plus insulin, and ovariectomized plus insulin plus estrogen. Chronic insulin and estrogen treatments were initiated with subcutaneous placement of insulin implants (2 U/d) and 17beta-estradiol implants (0.5 mg/pellet, 60 day release) at the back of the neck. After 8 weeks of treatment, mesenteric arteries were isolated for assessment of constrictor responses to norepinephrine and the thromboxane A2 analogue U46619 in the presence or absence of the endothelium. The results show that chronic estrogen treatment attenuated the vascular constrictor responses to norepinephrine and U46619 only in endothelium intact vessels. Incubation with insulin did not significantly affect norepinephrine-induced vascular smooth muscle contraction. The study provides evidence that the mechanism by which estrogen prevents insulin-induced blood pressure elevation in insulin-treated ovariectomized rats is by influencing endothelium-derived vasoactive factors such as thromboxane A2.


Subject(s)
Estradiol/pharmacology , Hypoglycemic Agents/pharmacology , Insulin Resistance , Insulin/pharmacology , Mesenteric Arteries/drug effects , Vasoconstriction/drug effects , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Implants , Estradiol/administration & dosage , Female , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Mesenteric Arteries/physiopathology , Norepinephrine/pharmacology , Ovariectomy , Rats , Rats, Wistar , Vasoconstrictor Agents/pharmacology
2.
Can J Physiol Pharmacol ; 80(10): 980-6, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12450064

ABSTRACT

We previously demonstrated that chronic endothelin receptor blockade (with bosentan) improved functional cardiac performance in streptozotocin-diabetic rats, suggesting a novel role of endothelin-1 (ET-1) in modulating diabetic heart dysfunction. To gain insight into the mechanism(s) underlying this effect, we examined the coronary vascular responses to ET-1 in hearts from diabetic and control rats treated with or without bosentan. Rats were divided into control, control-treated, diabetic, and diabetic-treated groups. The control-treated and diabetic-treated groups received bosentan (100 mg x kg(-1) x d(-1)) for 8 weeks. Following treatment, hearts were isolated and perfused, and coronary reactivity to ET-1 was assessed by measuring the changes in coronary perfusion pressure in response to ET-1 (50 and 100 pM). Additionally, maximal coronary blood flow (assessed with 10(-5) M adenosine) was measured in isolated perfused hearts. The key observation is that coronary reactivity to ET-1 was significantly higher in the diabetic than the control rats. This effect was normalized in diabetic rats chronically receiving bosentan. Maximal coronary vasodilation did not differ between the four groups. In conclusion, the reactivity of ET-1 is altered in the isolated perfused coronary vascular bed from diabetic rats, and chronic ET receptor blockade restores this reactivity to control values. These observations provide a possible mechanism for the improvement in diabetic heart function observed after chronic bosentan treatment.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Endothelin Receptor Antagonists , Endothelin-1/pharmacology , Sulfonamides/pharmacology , Vasoconstrictor Agents/pharmacology , Animals , Bosentan , Coronary Circulation/drug effects , Coronary Vessels/drug effects , Coronary Vessels/physiology , Diabetes Mellitus, Experimental/metabolism , Endothelin-1/physiology , In Vitro Techniques , Male , Rats , Rats, Wistar , Time Factors , Vasoconstriction/drug effects , Vasodilation/drug effects , Vasodilation/physiology
3.
Am J Physiol Heart Circ Physiol ; 283(2): H562-7, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12124202

ABSTRACT

Hyperinsulinemia and insulin resistance have been linked to hypertension; however, the influence of sex on this relationship has not been well studied. The purpose of this experiment was to compare the effects of chronic insulin treatment on insulin sensitivity and blood pressure in male and female rats. Male and female Wistar rats were treated with insulin (2 U/day) via subcutaneous sustained release implants for 5 wk. Systolic blood pressure was measured via the tail-cuff method before and after treatment, and insulin sensitivity was assessed with an oral glucose tolerance test. The insulin sensitivity of female rats was 4.5-fold greater than male rats. Chronic insulin treatment impaired insulin sensitivity in both sexes; however, this occurred to a greater degree in male rats. Blood pressure increased in male rats treated with insulin only. The results demonstrate that hyperinsulinemia and insulin resistance are associated with hypertension in male rats only. Therefore, the link between these conditions appears to depend on sex.


Subject(s)
Hyperinsulinism/complications , Hyperinsulinism/physiopathology , Hypertension/etiology , Insulin Resistance , Sex Characteristics , Animals , Blood Glucose/analysis , Blood Pressure , Female , Insulin/blood , Male , Rats , Rats, Wistar , Triglycerides/blood , Vasomotor System/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL